{"title":"FDA advisors unanimously green-light Moderna boosters for people 65+, high-risk","link":"https://arstechnica.com/?p=1804360","date":1634245761000,"content":"<div>\n<figure>\n  <img src=\"https://cdn.arstechnica.net/wp-content/uploads/2019/05/GettyImages-496532228-800x512.jpg\" />\n      <p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2019/05/GettyImages-496532228.jpg\">Enlarge</a> <span>/</span> The Food and Drug Administration headquarters in White Oak, Maryland. (credit: <a href=\"https://www.gettyimages.com/detail/news-photo/the-outside-of-the-food-and-drug-administration-news-photo/496532228?adppopup=true\">Getty | Congressional Quarterly</a>)</p>  </figure>\n\n\n\n\n\n\n<div><a name=\"page-1\"></a></div>\n<p>As expected, a committee of independent advisors for the Food and Drug Administration voted unanimously (19-to-0) Thursday afternoon in favor of authorizing a booster dose of Moderna's COVID-19 vaccine for certain groups.</p>\n<p>The groups flagged for boosting are individuals aged 65 and older, people ages 18 to 64 who are at risk of severe COVID-19 due to health concerns, and those 18 to 64 who are at risk of COVID-19 due to frequent institutional or occupational exposures, such as health care and essential workers. These are the same groups that were previously authorized to get a Pfizer/BioNTech booster.</p>\n<p>As with <a href=\"https://arstechnica.com/science/2021/09/fda-advisors-greenlight-pfizer-boosters-for-people-65-and-at-risk-groups/\">the Pfizer/BioNTech boosters</a>, the Moderna boosters are to be given six months or longer after the first two doses of Moderna's mRNA vaccine.</p></div><p><a href=\"https://arstechnica.com/?p=1804360#p3\">Read 11 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1804360&amp;comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"9aad8e4c78ea072fe394a703ae500da5715543bc975784c1a6c33530517ed842","category":"Tech"}